智通财经APP讯，乐普生物-B(02157)公布，国家药品监督管理局近期批准候选药物美佑恒® (注射用维贝柯妥塔单抗)在中国的上市申请，该药物为公司自主研发的一种表皮生长因子受体(EGFR)靶向创新型抗体药物偶联物(ADC)，用于治疗复发性或转移性鼻咽癌(R/M NPC)。
美佑恒® (注射用维贝柯妥塔单抗)是中国国内首个批准上市的EGFR靶向 ADC，为同类首创。美佑恒® (注射用维贝柯妥塔单抗)的获批是公司的又一重要里程碑，该药物用于治疗R/M NPC的获批上市将提升患者的治疗效果。公司也将基于此项获批进一步拓展美佑恒® (注射用维贝柯妥塔单抗)的适应症范围，加快转化其潜在商业价值。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.